The US authority attests that WILD meets the highest quality standards.

The guidelines of the Good Manufacturing Practice (GMP) are strict. The US Food and Drug Administration (FDA) was accordingly thorough in its recent audit of WILD GmbH. The auditors inspected the production and quality assurance systems for 2 days, focusing in particular on assembly, complaint management and management processes. The positive result of the audit: “No observations“.

For Head of Quality Management Emmerich Kriegl, the successful FDA audit is the consequence of WILD‘s commitment to quality. “The audit demonstrates our high level in process development and our distinct competencies in manufacturing and quality assurance“, says Kriegl. “In order to cooperate with the authorities in a targeted manner, you above all need a competent team to act swiftly and reliably while accompanying and supporting the staff.“ Therefore, WILD put together a specific project Team to prepare for the audit, in which Emmerich Kriegl himself, Markus Lippe, Martin Haubitz, Lukas Gruze and Wolfgang Pischounig played a crucial role. As part of the preparation, they meticulously reviewed the processes and evidence and continuously performed simulation audits, so-called mock inspections.